Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912691 · ClinicalTrials.gov registry record · Phase 3
A Trial of CM-AT in Children With Autism- Open Label Extension Study
A Phase 3 study, sponsored by Curemark.
- Completed
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
NCT00912691: Completed Phase 3 study, sponsored by Curemark.
NCT00912691 is a Phase 3 study that has completed, run by Curemark. The registered enrollment target is 165 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00912691, a Phase 3 study, has completed, sponsored by Curemark.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CM-AT is effective in treating the core symptoms of autism.
Interventions
- DRUG CM-AT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2010-01 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
What the finished NCT00912691 record still lists
NCT00912691 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which CM-AT is the first listed.
NCT00912691 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00912691 about?
NCT00912691 is a clinical study titled "A Trial of CM-AT in Children With Autism- Open Label Extension Study". The purpose of this study is to determine whether CM-AT is effective in treating the core symptoms of autism.
What is the current status of trial NCT00912691?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2010-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT00912691?
The interventions under investigation include: CM-AT (DRUG).
Who is sponsoring clinical trial NCT00912691?
This trial is sponsored by Curemark, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00912691's enrollment target sits among peer trials
165 1465th of 2000 higher than 531 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia